Company intelligence / Profile preview

Acarix

Ownership: Private
Development stage: Other

Overview

Acarix’s CADScor System is CE-marked and FDA De Novo-cleared for non-invasive, point-of-care rule-out of significant coronary artery disease. It has been used in over 40,000 patients and demonstrates at least 96% negative predictive value for ruling out significant CAD, reducing unnecessary invasive procedures[1][2][5].

Therapeutic areas: Cardiovascular
Modalities: DeviceNon-pharmacological therapy (acoustic-based diagnostic)
Industry: Physiological Monitoring

Partnerships

American College of Cardiology[6]Carnegie Investment Bank as Certified Advisor[5]Erik Penser Bank AB as Certified Advisor[1]

Beyond the preview

Go deeper on Acarix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acarix.

Explore the full profile